Colorectal Cancer

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

All patients with colorectal cancer being considered for treatment with the EGFR inhibitors cetuximab and panitumumab should undergo extended RAS mutational testing to predict their response to the drugs.

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).